Study · Animal study (in vivo) · mouse · 2025
16 resultsMarathe SJ, Grey EW, Bohm MS, Joseph SC, Ramesh AV, Cottam MA, Idrees K, Wellen KE, Hasty AH, Rathmell JC, Makowski L
npj metabolic health and disease14 Mar 2025Cited by 8 (Europe PMC)
16 results from studies that gave the peptide. No result from this study comes from people.
In preclinical cancer models, retatrutide caused significant weight loss.
In plain wordsIn mice with cancer, retatrutide treatment led to clear weight loss.
mousen: not reported in source
Source sentences
in pre-clinical models with significant retatrutide (RETA, LY3437943)-induced weight loss
In preclinical models with retatrutide-induced weight loss, pancreatic cancer engraftment was reduced.
In plain wordsIn mice with retatrutide-induced weight loss, fewer pancreatic cancer cells took hold.
mousen: not reported in source
Source sentences
We report that in pre-clinical models with significant retatrutide (RETA, LY3437943)-induced weight loss, pancreatic cancer engraftment was reduced, tumor onset was delayed, and progression was attenuated resulting in a 14-fold reduction in tumor volume compared to only 4-fold reduction in single agonist semaglutide-treated mice.
In preclinical models with retatrutide-induced weight loss, pancreatic tumor onset was delayed.
In plain wordsIn mice with retatrutide-induced weight loss, pancreatic tumours appeared later.
mousen: not reported in source
Source sentences
We report that in pre-clinical models with significant retatrutide (RETA, LY3437943)-induced weight loss, pancreatic cancer engraftment was reduced, tumor onset was delayed, and progression was attenuated resulting in a 14-fold reduction in tumor volume compared to only 4-fold reduction in single agonist semaglutide-treated mice.
In preclinical models with retatrutide-induced weight loss, pancreatic tumor progression was attenuated.
In plain wordsIn mice with retatrutide-induced weight loss, pancreatic tumours grew more slowly.
mousen: not reported in source
Source sentences
We report that in pre-clinical models with significant retatrutide (RETA, LY3437943)-induced weight loss, pancreatic cancer engraftment was reduced, tumor onset was delayed, and progression was attenuated resulting in a 14-fold reduction in tumor volume compared to only 4-fold reduction in single agonist semaglutide-treated mice.
In preclinical pancreatic cancer models, retatrutide gave a 14-fold reduction in tumor volume, compared with a 4-fold reduction with semaglutide.
In plain wordsIn mice with pancreatic cancer, retatrutide cut tumour volume 14-fold, compared with 4-fold for semaglutide.
mousen: not reported in source
Measurements
Source sentences
We report that in pre-clinical models with significant retatrutide (RETA, LY3437943)-induced weight loss, pancreatic cancer engraftment was reduced, tumor onset was delayed, and progression was attenuated resulting in a 14-fold reduction in tumor volume compared to only 4-fold reduction in single agonist semaglutide-treated mice.
In preclinical models, the anti-tumor benefits of retatrutide persisted after withdrawal despite weight re-gain.
In plain wordsIn preclinical models, the anti-tumour benefits of retatrutide lasted after treatment stopped, even though weight came back.
n: not reported in source
Source sentences
Despite weight re-gain after RETA withdrawal, the anti-tumor benefits of RETA persisted.
In preclinical models, body weight re-gain occurred after retatrutide withdrawal.
In plain wordsIn preclinical models, body weight came back after retatrutide was stopped.
n: not reported in source
Source sentences
Despite weight re-gain after RETA withdrawal, the anti-tumor benefits of RETA persisted.
In a preclinical lung cancer model, retatrutide reduced tumor engraftment by 50%.
In plain wordsIn a preclinical lung cancer model, retatrutide halved the number of tumours that took hold, compared with controls.
n: not reported in source
Measurements
Source sentences
Remarkably, RETA-induced protection extends to a lung cancer model with 50% reduced tumor engraftment, significantly delayed tumor onset, and mitigated tumor progression, with a 17-fold reduction in tumor volume compared to controls.
In a preclinical lung cancer model, retatrutide significantly delayed tumor onset.
In plain wordsIn a preclinical lung cancer model, retatrutide delayed the start of tumours compared with controls.
n: not reported in source
Source sentences
Remarkably, RETA-induced protection extends to a lung cancer model with 50% reduced tumor engraftment, significantly delayed tumor onset, and mitigated tumor progression, with a 17-fold reduction in tumor volume compared to controls.
In a preclinical lung cancer model, retatrutide mitigated tumor progression.
In plain wordsIn a preclinical lung cancer model, retatrutide slowed tumour progression compared with controls.
n: not reported in source
Source sentences
Remarkably, RETA-induced protection extends to a lung cancer model with 50% reduced tumor engraftment, significantly delayed tumor onset, and mitigated tumor progression, with a 17-fold reduction in tumor volume compared to controls.
In a preclinical lung cancer model, retatrutide gave a 17-fold reduction in tumor volume compared with controls.
In plain wordsIn a preclinical lung cancer model, retatrutide cut tumour volume 17-fold compared with controls.
n: not reported in source
Measurements
Source sentences
Remarkably, RETA-induced protection extends to a lung cancer model with 50% reduced tumor engraftment, significantly delayed tumor onset, and mitigated tumor progression, with a 17-fold reduction in tumor volume compared to controls.
In preclinical cancer models, retatrutide elevated circulating IL-6.
In plain wordsIn preclinical cancer models, retatrutide raised circulating IL-6, an immune signal.
n: not reported in source
Source sentences
RETA induced immune reprogramming systemically and in the tumor microenvironment with durable anti-tumor immunity evidenced by elevated circulating IL-6, increased antigen presenting cells, reduced immunosuppressive cells, and activation of pro-inflammatory pathways.
In preclinical cancer models, retatrutide increased antigen presenting cells.
In plain wordsIn preclinical cancer models, retatrutide increased immune cells that present antigens.
n: not reported in source
Source sentences
RETA induced immune reprogramming systemically and in the tumor microenvironment with durable anti-tumor immunity evidenced by elevated circulating IL-6, increased antigen presenting cells, reduced immunosuppressive cells, and activation of pro-inflammatory pathways.
In preclinical cancer models, retatrutide reduced immunosuppressive cells.
In plain wordsIn preclinical cancer models, retatrutide reduced immune cells that suppress immune attack.
n: not reported in source
Source sentences
RETA induced immune reprogramming systemically and in the tumor microenvironment with durable anti-tumor immunity evidenced by elevated circulating IL-6, increased antigen presenting cells, reduced immunosuppressive cells, and activation of pro-inflammatory pathways.
In preclinical cancer models, retatrutide activated pro-inflammatory pathways.
In plain wordsIn preclinical cancer models, retatrutide switched on pro-inflammatory pathways.
n: not reported in source
Source sentences
RETA induced immune reprogramming systemically and in the tumor microenvironment with durable anti-tumor immunity evidenced by elevated circulating IL-6, increased antigen presenting cells, reduced immunosuppressive cells, and activation of pro-inflammatory pathways.
In mice with pancreatic cancer, semaglutide produced a 4-fold reduction in tumor volume, smaller than the 14-fold reduction with retatrutide.
In plain wordsIn mice with pancreatic cancer, semaglutide cut tumor volume 4-fold, less than the 14-fold cut seen with retatrutide.
mousen: not reported in source
pre-clinical pancreatic cancer modelMeasurements
Source sentences
resulting in a 14-fold reduction in tumor volume compared to only 4-fold reduction in single agonist semaglutide-treated mice.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.
Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC
Terms as the source lists them.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated